MKC3946
MKC3946 is a potent IRE1α inhibitor, used for cancer research.
Product Specifications
CAS Number
[1093119-54-0]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
IRE1
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/MKC3946.html
Purity
99.79
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
O=CC1=C(O)C=CC2=C1C=CC(C3=CC=C(C(N4CCN(C)CC4)=O)S3)=C2
Molecular Formula
C21H20N2O3S
Molecular Weight
380.46
Precautions
H302, H315, H319, H335
References & Citations
[1]Sun H, et al. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget. 2016 Apr 5;7 (14) :18736-49|[2]Zhang L, et al. IRE1 inhibition perturbs the unfolded protein response in a pancreatic β-cell line expressing mutant proinsulin, but does not sensitize the cells to apoptosis. BMC Cell Biol. 2014 Jul 10;15:29.|[3]Mimura N, et al. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14;119 (24) :5772-81
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-19710/MKC3946-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-19710/MKC3946-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1189835-01 0.02 mg (E-Coli)
Recombinant Bacillus licheniformis Stage V sporulation protein AA (spoVAA)
Ask
View Details MBS1189835-02 0.1 mg (E-Coli)
Recombinant Bacillus licheniformis Stage V sporulation protein AA (spoVAA)
Ask
View Details MBS1189835-03 0.02 mg (Yeast)
Recombinant Bacillus licheniformis Stage V sporulation protein AA (spoVAA)
Ask
View Details